Roche reports positive study results with antihypertensive drug
Published: Tuesday, Mar 5th 2024, 14:00
Updated At: Tuesday, Mar 5th 2024, 14:00
Retour au fil d'actualité
Roche and the US company Alnylam have announced positive results from a study with the drug Zilebesiran. The antihypertensive drug met the primary endpoint after three months of treatment in the Phase 2 study called Kardia-2, Roche announced on Tuesday.
Zilebesiran has shown an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension in combination with standard therapy. The results would support the potential of biannual dosing.
The results of the Kardia-2 study are to be presented in April at the 2024 Annual Scientific Meeting of the American College of Cardiology. In addition, the Kardia-3 Phase II study in adults with uncontrolled high blood pressure and high cardiovascular risk is already underway.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic